BridgeBio Pharma, Inc. (BBIO) Social Stream
BRIDGEBIO PHARMA INC (BBIO) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering BRIDGEBIO PHARMA INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-05 | 8 | $88 | $68 | $79.625 | $8.85 | 799.72% |
| 2021-12-03 | 8 | $88 | $66 | $79.375 | $8.85 | 796.89% |
| 2022-01-18 | 8 | $86 | $17 | $41.125 | $8.85 | 364.69% |
| 2022-02-24 | 8 | $86 | $17 | $40.875 | $8.85 | 361.86% |
| 2022-02-28 | 8 | $86 | $17 | $40.375 | $8.85 | 356.21% |
| 2022-03-08 | 7 | $80 | $17 | $32 | $8.85 | 261.58% |
| 2022-03-15 | 7 | $80 | $17 | $31.857 | $8.85 | 259.97% |
| 2022-04-13 | 7 | $80 | $17 | $31.571 | $8.85 | 256.73% |
| 2022-05-05 | 7 | $80 | $17 | $32.142 | $8.85 | 263.19% |
| 2022-05-18 | 7 | $80 | $17 | $31.285 | $8.85 | 253.5% |
| 2022-05-24 | 7 | $27 | $17 | $22.571 | $8.85 | 155.04% |
| 2022-06-13 | 7 | $27 | $12 | $20.428 | $8.85 | 130.82% |
| 2022-06-17 | 7 | $27 | $13 | $20.571 | $8.85 | 132.44% |
| 2022-07-26 | 7 | $27 | $17 | $21.285 | $8.85 | 140.51% |
| 2022-08-13 | 7 | $30 | $17 | $21.714 | $8.85 | 145.36% |
| 2022-09-17 | 8 | $30 | $17 | $21.875 | $8.85 | 147.18% |
| 2022-11-03 | 8 | $26 | $17 | $21 | $8.85 | 137.29% |
| 2022-11-08 | 8 | $24 | $17 | $20.75 | $8.85 | 134.46% |
| 2022-11-11 | 8 | $24 | $16 | $20.5 | $8.85 | 131.64% |
| 2022-11-18 | 8 | $24 | $16 | $20.375 | $8.85 | 130.23% |
| 2023-01-06 | 8 | $24 | $15 | $20.25 | $8.85 | 128.81% |
| 2023-01-23 | 8 | $24 | $15 | $19.75 | $8.85 | 123.16% |
The Trend in the Analyst Price Target
Over the past 16 months, BBIO's average price target has gone down $60.65.
Over the past 51 weeks, BBIO's average upside potential has been 209.62%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-05-05 | 7 | 80 | 17 | 31.285 | 7.51 | 316.58% |
| 2022-05-24 | 7 | 27 | 17 | 22.571 | 6.72 | 235.88% |
| 2022-06-08 | 7 | 27 | 12 | 20.428 | 7.81 | 161.56% |
| 2022-07-26 | 7 | 30 | 17 | 21.714 | 9.29 | 133.74% |
| 2022-10-24 | 8 | 26 | 17 | 21.000 | 10.24 | 105.08% |
BBIO Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.13 | 7 | 1 | 0 | 0 | 0 | 8 |
The Trend in the Broker Recommendations
BBIO's average broker recommendation rating improved by 0 over the prior 14 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- BRIDGEBIO PHARMA INC's upside potential (average analyst target price relative to current price) is greater than 2207.17% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, BRIDGEBIO PHARMA INC's variance in analysts' estimates is lower than -1682.13% of them.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, BRIDGEBIO PHARMA INC's average analyst price target is higher than 998.42% of them.
- BBIO has a greater number of analysts covering the stock than 1543.49% of Pharmaceutical Products stocks.
Stocks similar to BRIDGEBIO PHARMA INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are MORF, STOK, and NGM.
View All Top Stocks by Price Target
What is the outlook for BBIO? Use POWR Ratings for clearer insight into price direction.